首页 | 本学科首页   官方微博 | 高级检索  
     


TERT- beyond the territory: Usage of PCR-based TERT promoter assay in defining urothelial carcinoma in a case of long-standing prostatic adenocarcinoma
Affiliation:1. Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA;2. Michigan Center for Translational Pathology, Ann Arbor, MI, USA;3. Rogel Cancer Center, Michigan Medicine, Ann Arbor, MI, USA;4. Department of Urology, University of Michigan Medical School, Ann Arbor, MI, USA;5. Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA;6. Howard Hughes Medical Institute, Ann Arbor, MI, USA;1. Department of Thoracic Surgery, The Second People’s Hospital of Nantong, Nantong, Jiangsu, China;2. Department of Radiation Oncology, Nantong Tumor Hospital, Nantong, Jiangsu, China;1. Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, PR China;2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, PR China;3. Institute of Pathology, Fudan University, Shanghai 200032, PR China;1. Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy;2. Department of Biomedicine and Prevention, University of Rome “Tor Vergata”, Italy;3. Fondazione Umberto Veronesi (FUV), Piazza Velasca 5, 20122, Milano, Mi, Italy;4. San Raffaele University, Via di Val Cannuta 247, 00166, Rome, Italy;5. UniCamillus, Saint Camillus International University of Health Sciences, Rome, Italy;6. “Diagnostica Medica” and “Villa dei Platani”, Avellino, Italy (Neuromed group), Italy
Abstract:
Keywords:Urothelial Carcinoma  Neuroendocrine  Prostatic adenocarcinoma  TERT promoter mutation
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号